Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Safety, Tolerability, and PK of Sebetralstat (KVD900) in Healthy Volunteers
NCT04349800Phase 1Completed
- Sponsor
- KalVista Pharmaceuticals
- Start
- Jan 2018
- Primary completion
- Sep 2018
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial of sebetralstat in hereditary angioedema (HAE) (10 arms), sponsored by KalVista Pharmaceuticals. Primary endpoints: Number of Subjects with Adverse Events, Number of Subjects with Serious Adverse Events and 3 more. Started Jan 2018; status: completed.
02
Drugs
sebetralstat
03
Conditions
hereditary angioedema (HAE)
Beyond the preview
Go deeper on NCT04349800.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04349800.